NASDAQ
84.84USD
-0.20 (-0.24%)
We have scored 17 news catalysts on Henry Schein, Inc. (HSIC) over the past 12 months. The biggest single-day move next to one of them came Nov 8, 2025, when HSIC closed +2.6%: “What Moved Markets This Week”. Coverage across the window leans positive (average ticker sentiment +0.46). Most of the impact sits in sector healthcare and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.7B
P/E
—
EPS
—
Beta
0.81
52W range
61.95-92.18
Day range
84.45–85.96
Open
84.84
Prev close
85.04
Volume
2.2M
Avg volume
1.3M
Dividend
0.00
IPO
1995-11-03
Analysts publish price targets on HSIC, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
8 analyst price targets from $85 to $110
as of 2026-09-06
The market is within 8% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Henry Schein, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for HSIC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
The price sits at the 25th percentile of the published model spread, endorsing the base case of low-to-mid single-digit growth and current margins, but explicitly declining to pay for the bull case of sustained high-single-digit revenue expansion.
What the disagreement turns on
Can dental and medical distribution volumes sustain the roughly 8% revenue growth the reverse-DCF requires, or will they revert to the 3-5% guidance the price otherwise assumes? Unit volume data can settle this, but pricing power cannot be tested with the wired tools.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $89.81 on 2026-09-06 — the quote has since moved -6%, so read this as a record of what was priced in then, not now.
